News Insights Into HIV Pathogenesis

17 March 1997

New research into the distribution of chemokine receptors in the bodyhas provided clues to how HIV infection may progress to AIDS, according to researchers at Harvard Medical School, the University of Pennsylvania and LeukoSite Inc. The work is reported in the Proceedings of the National Academy of Sciences (March 4).

The two receptors under study, CCR5 and CXCR4 (also known as Lestr or fusin), were recently identified as coreceptors, along with CD4, for the entry of HIV into immune cells. The researchers used antibodies to map the distribution of the two receptors, and report that the CCR5 receptor is found mainly on memory T cells, while CXCR4 is found on naive cells.

This work follows studies which have demonstrated that HIV-1 strains have distinct cellular tropisms, ie they are either M-tropic (infecting macrophages and primary T cells), or T-tropic (able to infect primary T cells but not monocytes or macrophages). Last year, CXCR4 was found to allow entry of T-tropic strains into CD4 cells, while CCR5 was found to be the major coreceptor for M-tropic HIV-1. More recently, it has been suggested that a mutation in the CCR5 gene renders individuals resistant to HIV infection, which argues strongly that M-tropic strains are critical for establishing infection.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight